Company news

Geron Corporation news in 2025

Geron Corporation's news releases, calls and decks from 2025, newest first.

View company

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 17, 2025

Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation

December 10, 2025

Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS

December 7, 2025

Geron Corporation Reports Third Quarter 2025 Financial Results and Recent Business Highlights

November 4, 2025

Geron Corporation to Present at Upcoming Investor Conferences

November 3, 2025

Geron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic Malignancies

November 2, 2025

Geron Plans to Announce Third Quarter 2025 Financial Results on November 5, 2025

October 26, 2025

Cassava Sciences Appoints Dawn C. Bir to the Board of Directors

October 22, 2025

Geron Corporation Announces Executive Leadership Transitions and Appointments

October 12, 2025

Geron to Participate in the 2025 Wells Fargo Healthcare Conference

August 26, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

August 19, 2025

Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 7, 2025

Geron Appoints Harout Semerjian as President and Chief Executive Officer

August 6, 2025

Geron Corporation Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 5, 2025

Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 27, 2025

Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

May 27, 2025

Geron Corporation Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 6, 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 17, 2025

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

March 30, 2025

Geron Corporation Announces Departure of Chief Executive Officer

March 10, 2025

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

March 10, 2025

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

February 25, 2025

Geron to Participate at Upcoming Investor Conferences in March 2025

February 20, 2025

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

February 2, 2025

Calls in 2025

Decks in 2025